Wei Xu

49PUBLICATIONS
29CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Jul 10, 2026
R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study.

|Jul 05, 2026
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

|Feb 11, 2026
Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial.

Hao-Rui Shen, Jia-Zhu Wu, Hua Yin

|Jul 30, 2025
PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC-Mediated Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma.

Wei-Ting Wang, Zi-Wen Duan, Tong-Yao Xing

|Mar 05, 2025
SH3GL1-activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B-cell lymphoma.

Zi-Wen Duan, Wei-Ting Wang, Yan Wang

|Dec 28, 2024
Revealing the heterogeneity of treatment resistance in less-defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy.

Wei Hua, Jie Liu, Yue Li

Pageof 9

Frequent Collaborators

7 joint publications

Li Jian-Yong

4 joint publications

Yi Miao

3 joint publications

Jianyong Li

3 joint publications

Lei Fan